To explore this possibility, we utilized a mouse model of diabetic nephropathy (uninephrectomy and streptozotocin (STZ) treatment) to examine the effect of siRNA-induced Gremlin inhibition in vivo on the progression of renal pathology. This evidence concerns the gene GREM1 and diabetic kidney disease.